Xenon Pharmaceuticals Inc. — Director's Dealing 2021

Jun 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2021-03-17

Reporting Person: PATOU GARY (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-17	Common Shares	L	100	$19.49	Acquired	100	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-03	Stock Option (Right to Buy)	$18.56	A	10000	Acquired	2031-06-02	Common Shares (10000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	12500	Indirect
Common Shares	23573	Direct

Footnotes

F1: Shares acquired by the reporting person's son sharing the reporting person's household on the date of acquisition. Subsequent to the acquisition of the reported shares, the reporting person's son no longer shares a household with the reporting person and the reporting person no longer has a reportable beneficial interest in such shares. Subsequent ownership reports filed by the reporting person will not report these shares.

F2: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.

F3: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to
the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year
anniversary of the grant date.